| abstract |
PCT No. PCT/EP96/05637 Sec. 371 Date Jun. 16, 1998 Sec. 102(e) Date Jun. 16, 1998 PCT Filed Dec. 16, 1996 PCT Pub. No. WO97/23485 PCT Pub. Date Jul. 3, 1997Compounds of formula I and pharmaceutically acceptable salts thereof in which A is methylene or -O-; B is methylene or -O-; G1-G2-G3 are absent or form a heteroaromatic chain; g is 0,1,2,3 or 4; U is an alkylene chain optionally substituted by one or more alkyl; Q represents a divalent group containing nitrogen atoms; and T represents CO. HET, have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mrellitus, hyperglvcaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity. |